LIGAND PHARMA
LIGAND PHARMA operates in Diversified Metals & Mining.
LIGAND PHARMA (LGDN) - Total Assets
Latest total assets as of September 2024: €954.87 Million EUR
Based on the latest financial reports, LIGAND PHARMA (LGDN) holds total assets worth €954.87 Million EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LIGAND PHARMA - Total Assets Trend (2016–2023)
This chart illustrates how LIGAND PHARMA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LIGAND PHARMA - Asset Composition Analysis
Current Asset Composition (December 2023)
LIGAND PHARMA's total assets of €954.87 Million consist of 30.2% current assets and 69.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.9% |
| Accounts Receivable | €32.92 Million | 4.2% |
| Inventory | €23.97 Million | 3.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €366.90 Million | 46.6% |
| Goodwill | €103.37 Million | 13.1% |
Asset Composition Trend (2016–2023)
This chart illustrates how LIGAND PHARMA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LIGAND PHARMA's current assets represent 30.2% of total assets in 2023, an increase from 27.1% in 2016.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2023, down from 3.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 50.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 46.6% of total assets.
LIGAND PHARMA Competitors by Total Assets
Key competitors of LIGAND PHARMA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
LIGAND PHARMA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LIGAND PHARMA generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, LIGAND PHARMA generates $6.63 in net profit.
LIGAND PHARMA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.49 | 16.15 | 66.09 |
| Quick Ratio | 11.95 | 14.54 | 65.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €284.62 Million | € 238.27 Million | € 1.11 Billion |
LIGAND PHARMA - Advanced Valuation Insights
This section examines the relationship between LIGAND PHARMA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.2% |
| Total Assets | €787.22 Million |
| Market Capitalization | $1.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values LIGAND PHARMA's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: LIGAND PHARMA's assets grew by 3.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for LIGAND PHARMA (2016–2023)
The table below shows the annual total assets of LIGAND PHARMA from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €787.22 Million | +3.22% |
| 2022-12-31 | €762.67 Million | -41.22% |
| 2021-12-31 | €1.30 Billion | -4.75% |
| 2020-12-31 | €1.36 Billion | -8.87% |
| 2019-12-31 | €1.49 Billion | +18.57% |
| 2018-12-31 | €1.26 Billion | +87.89% |
| 2017-12-31 | €671.02 Million | +11.54% |
| 2016-12-31 | €601.59 Million | -- |